NovaBridge Biosciences (NBP) Accumulated Depreciation (2020 - 2021)
NovaBridge Biosciences (NBP) posted quarterly Accumulated Depreciation of -$5.7 billion for Q2 2021, down 23.3% quarter-over-quarter from -$4.7 billion in Q4 2020.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Accumulated Depreciation (2020 - 2021) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Accumulated Depreciation for 2 consecutive years, with -$5.7 billion the latest figure, recorded in Q2 2021.
- In Q2 2021, Accumulated Depreciation changed N/A year-over-year to -$5.7 billion; the TTM figure through Jun 2021 stood at -$5.7 billion (changed N/A YoY), while the FY2020 annual figure was -$4.7 billion, changed N/A from the prior year.
- Accumulated Depreciation slipped to -$5.7 billion in Q2 2021 per NBP's latest filing, from -$4.7 billion in the prior quarter.
- Across five years, Accumulated Depreciation topped out at -$4.7 billion in Q4 2020 and bottomed at -$5.7 billion in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - |